<DOC>
	<DOCNO>NCT02168725</DOCNO>
	<brief_summary>The main objective study determine safety profile briciclib , experimental anti-cancer drug , administer intravenously weekly escalate dos adult patient advance cancer solid tumor , determine high dose briciclib safely give . Secondary objective determine amount briciclib circulation change time much briciclib get urine excretion , document potential anti-tumor effect briciclib .</brief_summary>
	<brief_title>Dose-escalation , Safety Pharmacokinetic Study Briciclib Advanced Solid Tumors</brief_title>
	<detailed_description>This Phase I , 2-stage , open-label , dose-escalating , multicenter study 2-hour , once-a-week intravenous ( IV ) administration briciclib 3-week cycle , 54 adult patient advance cancer solid tumor . The study conduct 2 stage : dose-escalation stage determine Maximum Tolerated Dose ( MTD ) Recommended Phase 2 Dose ( RPTD ) confirmation stage . Patients stable disease ( SD ) response may remain treated study progression .</detailed_description>
	<criteria>1 . Histologically confirm solid tumor ( leukemia lymphoma exclude ) 2 . Malignancy incurable standard ( FDA approve establish standard clinical practice ) curative , palliative measure exist longer effective 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 4 . Minimum expect life expectancy &gt; 6 month 5 . One measurable lesion ( ) ( `` target lesion [ ] '' ) accurately measure least 1 dimension 6 . Willing adhere prohibition restriction specify protocol 7 . The patient must sign informed consent form ( ICF ) 1 . Recent major surgery ( within past 14 day ) 2 . Chemotherapy dose potentially myelosuppressive treatment within 3 week prior Screening ( 6 week nitrosoureas mitomycin C ) 3 . No total cumulative dose 450 mg/m^2 prior doxorubicin chemotherapy 4 . Definitive radiotherapy ( &gt; 10 fraction maximal area hematopoietic active Bone Marrow treat great 25 % ) within 4 week prior Screening 5 . Palliative radiotherapy ( ≤ 10 fraction ) within 2 week prior Screening 6 . Known brain metastasis , except brain metastasis previously remove irradiate currently clinical impact 7 . Residual adverse event due previously administer agent ( except alopecia , stable residual neuropathy , residual hand , foot syndrome ) recover Grade 1 severity level ( base NCI CTCAE ) Screening 8 . Ascites require active medical management , include paracentesis 9 . Pleural effusion require active medical management 10 . Peripheral bilateral edema require active medical management 11 . Hyponatremia ( serum sodium value le 130 mEq/L ) 12 . History allergic reaction attribute compound similar chemical biologic composition briciclib 13 . Uncontrolled intercurrent illness include , limited , ongoing active infection , bleeding , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement 14 . History myocardial infarction 15 . Any concurrent investigational agent chemotherapy , radiotherapy , hormonotherapy , immunotherapy . Exceptions longterm hormonals prostate ( eg , goserelin ) octreotide neuroendocrine malignancy 16 . Patients positive human immunodeficiency virus type 1 ( HIV1 ) receive combination antiretroviral therapy 17 . Hemoglobin ( Hgb ) &lt; 9 g/dL 18 . White Blood Cell count ( WBC ) &lt; 4,000/µL 19 . Absolute Neutrophil Count ( ANC ) &lt; 1,500/µL 20 . Platelet ( PLT ) count ≤ 100,000/µL 21 . Total bilirubin great 1.5 x institutional upper limit normal ( ULN ) 22 . Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≥ 2.5 x institutional ULN . If liver function abnormality due metastatic disease , patient eligible provided ALT AST &lt; 5 x ULN 23 . Serum creatinine &gt; 2 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>briciclib</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Maximum tolerate dose</keyword>
</DOC>